Urine test for ovarian cancer detection and tracking
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at proteins in urine to help find ovarian cancer earlier and track how the disease changes. It aims to provide a non-invasive way to tell the difference between benign and malignant pelvic masses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman scheduled for gynecological surgery.
- You have a pelvic mass, swollen belly from fluid, or a non-cancerous condition like an ovarian cyst or fibroids.
- You are at least 18 years old.
- You agree to take part and sign a consent form.
- You have not had cancer before.
- You do not have chronic kidney disease or kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a sample of fluid from the uterus (uterine lavage) can help detect ovarian or fallopian tube cancer. You may join if you are having certain gynecologic surgeries or, in a smaller group, you have a BRCA1/2 mutation.
This trial checks whether a “liquid biopsy,” a blood test, can help doctors tell apart different causes of a suspicious pelvic/ovarian mass and help with early detection. It may help avoid uncertainty before surgery by adding test results from blood along with imaging and standard markers.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
Hear when a new Ovarian Cancer (OvCa) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.